About Illumigen
Illumigen is a company based in Osaka (Japan) founded in 2000 was acquired by Cubist Pharmaceuticals in December 2007.. Illumigen has raised $956.85 thousand across 1 funding round from investors including Cubist Pharmaceuticals. Illumigen operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Osaka, Japan
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$956.85 K (USD)
in 1 rounds
-
Latest Funding Round
$956.85 K (USD), Seed
Oct 29, 2007
- Investors
-
Employee Count
Employee Count
-
Acquired by
Cubist Pharmaceuticals
(Dec 24, 2007)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Illumigen
Illumigen has successfully raised a total of $956.85K through 1 strategic funding round. The most recent funding activity was a Seed round of $956.85 thousand completed in October 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $956,845
-
First Round
First Round
(29 Oct 2007)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2007 | Amount | Seed - Illumigen | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Illumigen
Illumigen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cubist Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Illumigen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Illumigen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Illumigen Comparisons
Competitors of Illumigen
Illumigen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Illumigen
When was Illumigen founded?
Illumigen was founded in 2000 and raised its 1st funding round 7 years after it was founded.
Where is Illumigen located?
Illumigen is headquartered in Osaka, Japan. It is registered at Osaka, Osaka Prefecture, Japan.
Is Illumigen a funded company?
Illumigen is a funded company, having raised a total of $956.85K across 1 funding round to date. The company's 1st funding round was a Seed of $956.85K, raised on Oct 29, 2007.
What does Illumigen do?
Illumigen was established in 2000 as a pharmaceutical company based in the United States. Focus was placed on developing treatments for infectious conditions, such as hepatitis C virus, respiratory syncytial virus, and related areas including obesity. Drug candidates were advanced through research and preclinical stages. Acquisition by Cubist Pharmaceuticals took place in December 2007, after which independent operations ceased.
Who are the top competitors of Illumigen?
Illumigen's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Who are Illumigen's investors?
Illumigen has 1 investor. Key investors include Cubist Pharmaceuticals.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.